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Résumé 
La douleur neuropathique est définie comme une douleur causée par une lésion du système nerveux 
somato-sensoriel. Elle se caractérise par des douleurs exagérées, spontanées, ou déclenchées par 
des stimuli normalement non douloureux (allodynie) ou douloureux (hyperalgésie). Bien qu'elle 
concerne 7% de la population, ses mécanismes biologiques ne sont pas encore élucidés. L'étude des 
variations d'expressions géniques dans les tissus-clés des voies sensorielles (notamment le ganglion 
spinal et la corne dorsale de la moelle épinière) à différents moments après une lésion nerveuse 
périphérique permettrait de mettre en évidence de nouvelles cibles thérapeutiques. Elles se détectent 
de manière sensible par reverse transcription quantitative real-time polymerase chain reaction (RT-
qPCR). Pour garantir des résultats fiables, des guidelines ont récemment recommandé la validation 
des gènes de référence utilisés pour la normalisation des données ("Minimum information for 
publication of quantitative real-time PCR experiments", Bustin et al 2009). 
Après recherche dans la littérature des gènes de référence fréquemment utilisés dans notre modèle de 
douleur neuropathique périphérique SNI (spared nerve injury) et dans le tissu nerveux en général, nous 
avons établi une liste de potentiels bons candidats: Actin beta (Actb), Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH), ribosomal proteins 18S (18S), L 13a (RPL 13a) et L29 (RPL29), hypoxanthine 
phosphoribosyltransferase 1 (HPRT1) et hydroxymethyl-bilane synthase (HMBS). Nous avons évalué la 
stabilité d'expression de ces gènes dans le ganglion spinal et dans la corne dorsale à différents 
moments après la lésion nerveuse (SNI) en calculant des coefficients de variation et utilisant 
l'algorithme geNorm qui compare les niveaux d'expression entre les différents candidats et détermine la 
paire de gènes restante la plus stable. Il a aussi été possible de classer les gènes selon leur stabilité et 
d'identifier le nombre de gènes nécessaires pour une normalisation la plus précise. 
Les gènes les plus cités comme référence dans le modèle SNI ont été GAPDH, HMBS, Actb, HPRT1 et 
18S. Seuls HPRT1 and 18S ont été précédemment validés dans des arrays de RT-qPCR. Dans notre 
étude, tous les gènes testés dans le ganglion spinal et dans la corne dorsale satisfont au critère de 
stabilité exprimé par une M-value inférieure à 1. Par contre avec un coefficient de variation (CV) 
supérieur à 50% dans le ganglion spinal, 18S ne peut être retenu. La paire de gènes la plus stable 
dans le ganglion spinal est HPRT1 et Actb et dans la corne dorsale il s'agit de RPL29 et RPL 13a. 
L'utilisation de 2 gènes de référence stables suffit pour une normalisation fiable. 
Nous avons donc classé et validé Actb, RPL29, RPL 13a, HMBS, GAPDH, HPRT1 et 18S comme 
gènes de référence utilisables dans la corne dorsale pour le modèle SNI chez le rat. Dans le ganglion 
spinal 18S n'a pas rempli nos critères. Nous avons aussi déterminé que la combinaison de deux gènes 
de référence stables suffit pour une normalisation précise. Les variations d'expression génique de 
potentiels gènes d'intérêts dans des conditions expérimentales identiques (SNI, tissu et timepoints 
post SNI) vont pouvoir se mesurer sur la base d'une normalisation fiable. Non seulement il sera 
possible d'identifier des régulations potentiellement importantes dans la genèse de la douleur 
neuropathique mais aussi d'observer les différents phénotypes évoluant au cours du temps après 
lésion nerveuse. 
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Research Notes 
Reverse transcription quantitative real-time 
polymerase chain reaction reference genes in the 
spared nerve injury model of neuropathie pain: 
validation and literature search 
Nicolas Piller1, Isabelle Decosterd 1•2 and Marc R Suter1' 
Abstract 
Background: The reverse transcription quantitative real-time polymerase chain reaction (RT-qPCR) is a widely used, 
highly sensitive laboratory technique to rapidly and easily detect, identify and quantify gene expression. Reliable 
RT-qPCR data necessitates accurate normalization with validated contrai genes (reference genes) whose expression is 
constant in ail studied conditions. This stability has to be demonstrated. 
We performed a literature search for studies using quantitative or semi-quantitative PCR in the rat spared nerve injury 
(SNI) model of neuropathie pain to verify whether any reference genes had previously been validated. We then analyzed 
the stability over time of 7 commonly used reference genes in the nervous system - specifically in the spinal cord dorsal 
horn and the dorsal root ganglion (DRG). These were: Actin beta (Actb), Glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH), ribosomal proteins 18S (18S), L 13a (RPL 13a) and L29 (RPL29), hypoxanthine phosphoribosyltransferase 1 
(HPRT1) and hydroxymethylbilane synthase (HMBS). We compared the candidate genes and established a stability 
ranking using the geNorm algorithm. Finally, we assessed the nurnber of reference genes necessa1y for accu rate 
normalization in this neuropathie pain model. 
Results: We found GAPDH, HMBS, Actb, HPRTl and 18S cited as reference genes in literaMe on studies using the SNI 
model. Only HPRTl and 18S had been once previously demonstrated as stable in RT-qPCR arrays. Ali the genes tested in 
this study, using the geNorm algorithm, presented gene stability values (M-value) acceptable enough for them to qualify 
as potential refe1·ence genes in both DRG and spinal cmd. Using the coefficient of variation, l 8S failed the 50% eut-off 
with a value of 61 % in the DRG. The two most stable genes in the dorsal hom were RPL29 and RPL l 3a; in the DRG they 
were HPRT1 and Actb. Using a 0.15 eut-off for pairwise variations we found that any pair of stable reference gene was 
sufficient for the normalization process. 
Conclusions: ln the rat SNI model, we validated and ranked Actb, RPL29, RPL 13a, HMBS, GAPDH, HPRTl and l 8S as 
good reference genes in the spinal cord. ln the DRG, 18S did not fulfill stability criteria. The combination of any two 
stable reference genes was sufficient to provide an accu rate normalization. 
Keywords: Neuropathie pain, Spared nerve injury, Reference gene, RT-qPCR, Rat 
* Correspondence: marc.suter@chuv.ch 
1 Pain (enter, Department of Anesthesiology, University Hospital (enter and 
University of Lausanne, Avenue du Bugnon 46, 1011 Lausanne, Switzerland 
Full list of author information is available at the end of the article 
() Central © 2013 Piller et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution Ucense (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and 
reproduction in any medium, provided the original work is properly cited. 
3 
Piller et al. BMC Research Notes 2013, 6:266 
http://www.biomedcentral.com/17 56-0500/6/266 
Background 
While 20%-30% of the general populace are af±:ected by 
chronic pain, a significant proportion, about 7%, experi-
ences neuropathie pain characteristics [1,2]. Defined by 
the International Association for the Study of Pain (IASP) 
as a pain "caused by a lesion or disease of the somatosen-
sory nervous system", neuropathie pain represents a daily 
challenge to medieal practiee and a wor!dwide public 
health problem since it is often refractory to treatment. 
Severa! animal models of neuropathie pain are used to 
study its different pathophysiologieal mechanisms and 
hopefully uncover new targets for treatment. Among 
them, the spared nerve injmy (SNI) mode! [3] represents 
an easy-to-perform and robust mode! of peripheral nerve 
injury. The axotomy of the tibial and peroneal branches 
of the sciatie nerve, sparing the sural nerve, allows a 
straightforward testing of the hind paw's sural nerve ter-
ritory for signs of hyperalgesia. After a peripheral nerve 
injury in rodents, numerous alterations in the somato-
sensory nervous system qm be observed, whieh together 
lead to a hyperexcitability of the system (4). Besicles 
changes affecting the primary nociceptors whose cell 
bodies are in the dorsal root ganglion (DRG) or the sec-
onda1y neurons in the dorsal horn projecting into the 
brain, glial cells also react dramatically to a peripheral 
nerve injmy like SNI. A common approach used to eluci-
date such changes in molecular machinery is to explore 
modifications in the expression of relevant genes [5,6). 
These variations can be detected and quantified in a sensi-
tive, specific way using a reverse transcription quantitative 
real-time polymerase chain reaction (RT-qPCR), assuming 
that an accurate normalization has been performed with 
reference genes that have proved stable in ail biological 
replicates and experimental conditions [7-10). The recently 
published guidelines on the "minimum information for 
publication of quantitative real-time PCR experiments" 
(MIQE) strongly recomrnended the validation of reference 
genes used in different cell types and conditions [7]. These 
guidelines outline the importance of RT-qPCR accuracy 
and recommend following detailed procedures to produce 
the most robust and reproducible RT-qPCR data. 
Algorithms like geNorm or NormFinder were devel-
oped to help researchers assess candidate reference 
genes. GeNorm has been well described [9) and widely 
accepted as a very useful tool for the normalization of 
RT-qPCR data [11). It measures the stability of potential 
reference genes by comparing their expression levels 
against one another. The expression ratio is supposed to 
be the same in all biological and technieal replicates. 
This pairwise comparison permits the assessment and 
ranldng of candidate reference genes and additionally 
demonstrates how many are necessary for an accurate 
normalization [9,11). To our knowledge, a validation of 
reference genes for the rat after spared nerve injury had 
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never been published. \XIe therefore performed a litera-
ture search for all studies using quantitative or semi-
quantitative PCR in the SNI mode! and listed all the 
reference genes used. W/ e then tested a total of 7 genes -
including commonly used reference genes in the nervous 
system and those used in the SNI mode! - at differ-
ent time points after nerve lesion in the spinal cord 
dorsal horn and in the DRG. These genes were Actin 
beta (Actb), Glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH), ribosomal proteins 18S (18S), Ll3a (RPL13a) 
and L29 (RPL29), hypoxanthine phosphoribosyltransferase 
1 (HPRTl) and hydrox1rmethylbilane synthase (HMBS) 
[12-15). Selected genes were related to varions meta-
bolic pathways to avoid any co-regulation [9]. 
Methods 
Animais 
We carried out our experiments on Sprague-Dawley rats 
(Charles River, L'Abresle, France) weighing 250-300 grams. 
They were housed under 12 h day/night photoperiodic 
conditions, at a constant temperature and with free access 
to water and food. Al! procedures were approved by the 
Canton of Yaud's Animal Experimentation Committee and 
were in accordance with the Swiss Federal Law on Animal 
\Xle[fare and the IASP's guidelines [16). 
Surgery 
Rats were anesthetized with isoflurane 1.5%-2.5% (Abott, 
Baat~ Switzer!and) and surgical procedures were performed 
as previously described [3,17). Briefly, the left sciatic nerve 
was exposed at the mid-thigh level distal to the trifurca-
tion, tibial and comrnon peroneal branches were tightly 
ligated with 5.0 silk and axotomized, leaving the sural 
branch intact. Muscle and skin were closed in two layers 
and animais were allowed to recover. Three rats were 
sacrificed at 2, 4, 7, 10, 14 and 21 days after surge1y. 
Literature search 
W e performed a literature search in the PubMed database 
using the keywords "spared nerve injury" and selected 
every study using semi-quantitative PCR or RT-qPCR in 
the rat SNI mode! (13 April 2013). We only selected arti-
cles in English. Reference genes used were noted, as were 
indications of their validation in the models. 
RNA isolation and reverse transcription 
Animals were transcardially perfused with NaCI 0.9% in 
order to expel the blood from collected tissue. Ipsilateral 
L4 and L5 DRG and spinal cord dorsal horn were rapidly 
dissected and immediately stored in RNA!ater'' (Qiagen, 
Switzerland) for stabilization at 4°C overnight, and then 
frozen at -80°C until processed. Samples were first 
homogenized with a POLYTRON° homogenizer and 
then total RNA was extracted using the RNeasy Plus 
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Mini Kit (Qiagen). To ensure complete removal of 
gDNA, we treated the dorsal horn samples. with a 
DNase (RNAqueous"-4PCR Kit, Ambion) and then the 
inactivation reagent recommended in the manufac-
turer's instructions. 
Nucleic acid purity was assessed measuring the 
A26o/A280 ratio by spectrophotometer (NanoDrop). 
Total RNA integrity (RIN) and quantity were deter-
mined with an Agilent 2100 Bioanalyser (Agilent 
Technologies). RNA used had to have bath a A260/ 
A280 ratio between 1.8 and 2.1, as well as a RIN ~8 
for dorsal horn RNA extractions and ~6.9 for DRG 
samples. The reverse transcription was achieved using 
Omniscript RT Kit (Qiagen), according to manufac-
turer's instructions. All reactions took place for lh at 
37°C in a final volume of 40 ~tl containing 1 µg total 
RNA in the presence of 20 units RNase inhibitor 
(RNasin" Ribonuclease Inhibitor, Promega), 1 µg ran-
dom hexamers (Microsynth), 4 µl lOx Buffer RT, 0.5 
mM dNTPs and 8 ur\its Omniscript reverse tran-
scriptase (Omniscript RT Kit, Qiagen). 
Table 1 Specification of used reference genes 
Gene symbol 
Full name 
Accession number 
Sequence (S'->3') 
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Selection of reference genes and primer design 
Reference genes were chosen from those used previ-
ously in the SNI model. Other potentially suitable ref-
erence genes were selected among those used in 
published literature on the nervous system (Table 1). 
\Xfhenever possible, primers fulfilled the following 
recommended criteria: amplicon length of 60 bp-150 
bp, location of primers on two different exons, primer 
sequence length of 18 bp-25 bp, melting temperature 
of 60°C +/-l°C and GC content of 40%-60% 
[7,18-20]. Primer specificity was checked in silico 
(Primer-BLAST Tool from http://www.ncbi.nlm.nih. 
gov/tools/primer-blast/) (21]. Ali oligonucleotides 
were supplied unmodified and desalted (Microsynth 
AG, Switzerland). 
Quantitative real-time PCR (qPCR) 
We performed qPCR on an iQ5 Cycler (Bio-Rad) 
with SYBR Green I. The reactions were carried out 
in 96-well plates (Thermo-Fast0 96 Semi-Skirted PCR 
Plate, Thermo Scientific, Switzerland) each with a 
Position Product lntron RTqPCR efficiency Ref. 
length inclusion in DH/DRG 
185 Fw:GGCTCATTAAATCAGTTATGGTTCCT 94-119 147 no 78%/70% [22] 
185 ribosomal RNA 
V01270 
RPL29 
Ribosomal protein L29 
NM_017150 
RPL13a 
Ribosomal protein L 13A 
NM_173340 
Actb 
Actin, beta 
l~M_031144 
HPRT1 
Hypoxanthine phosphoribosyl-transferase 1 
NM_012583 
HMBS 
Hydroxymethyl-bilane synthase 
NM_013168 
GAPDH 
Glyceraldehyde-3-phosphate 
dehydrogenase 
NM_017008 
Rev: GTTGGTTTTGATCTGATAAATGCACG 
Fw:ACAGAAATGGCATCAAGAAACCC 
Rev: TCTTGTTGTGCTTCTTGGCAAA 
Fw:TCTCCGAAAGCGGATGAACAC 
Rev: CAACACCTTGAGGCGTTCCA 
Fw:GGAGATTACTGCCCTGGCTCCTA 
Rev:GACTCATCGTACTCCTGCTTGCTG 
Fw:GCATCTAAGAGGTTTCCCCAGT 
Rev: GCA TTT AAAAGGAACGGTTGAC 
Fw:GAGACCATGCAGGCCACCAT 
Rev: TTGGAATGTTCCGGGCAGTG 
Fw:CCCCCAATGTATCCGTTGTG 
Rev: TAGCCCAGGATGCCCTTT AGT 
Fw forward, Rev reverse primer sequence, OH dorsal horn, DRG dorsal root ganglion. 
1 from our laboratory database. 
240-215 
96-118 105 yes 81%/77% [15] 
200-179 
185-205 145 yes 88%/73% [14) 
329-310 
1023-1045 150 yes 85%/63% [14] 
1172-1149 
1133-1154 76 no 70%/74% 
1208-1187 
1007-1026 97 yes 78%/72% [15] 
1084-1103 
780-799 118 yes 89%/87% [23] 
877-897 
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total volume of 20 µ!. Each well contained 5 µ! of a 
100-fold dilution of cDNA, 10 µ! of iQ~ Sybr0 Green 
Supermix (2x qPCR mix contains dNTPs, 50 U/ml 
iTaq DNA polymerase, 6 mM MgC12, SYBR Green I, 
enhancers, stabilizers, 20 nM fluorescein) (Bio-Rad, 
Switzerland), 2 µl of each primer 1-3 µM and 1 µ! 
water. We optimized qPCR conditions on the iQ5 
thermal gradient cycler and by testing different con-
centrations of primers and templates. The qPCR pro-
gram began with an initial three-minute denaturation 
step at 95°C to activate the hot-start iTaq'" DNA polymer-
ase. This was followed by 45 cycles of 10 s at 95°C 
for denaturation and 45 s at 60°C for annealing and 
extension. 
\X! e confirmed the amplification of specific qPCR 
products by perfonning a melting-curve step at the 
end of each run. Serial dilution curves for each primer 
allowed us to calculate qPCR efficiencies. The 100-
fold diluted cDNA utilized for all the amplifications 
was within the linear dy1rnmic range of the calibration 
curve between 10 and 1000-fold dilution. Across 
al! the assays, none of the quantification cycle (Cq) 
values was higher than 30. No-template and no-
reverse transcription controls were run to determine 
any contamination or the generation of primer di-
mers. Al! amplifications were run in triplicate, and 
any doubtful curves were excluded. To minimize 
technical variation between samples through differ-
ent runs we preferred the sample maximization 
method [11], i.e. a run contained ail the samples for 
one gene of interest respective to one reference 
gene. 
Data analysis 
Raw data was collected and computed by iQ5 BioRad 
software with an automated analysis of the baseline and 
threshold of each run, and then exported in Excel files 
for further analyses. We rescaled all Cq values for each 
gene to the lowest Cq value as an interna! contra!, 
converted these rescaled Cq logaritlunically into linear, 
relative quantities taking into account the gene specific 
amplification efficiency [relative quantity = (1 +efficiency) /\ 
(Cqinternal control_Cqsample)]. Finally, we calculated arithmet-
ical means from the replicates [11,24]. To explore the sta-
bility of each candidate gene we calculated M-values from 
the geNorm algorithm and coefficients of variation (CV) 
[9,11]. The M-value corresponds to the average pairwise 
variation between a gene and the other candidate genes. 
The more this value tends to zero, the more stably the 
gene is expressed in comparison to the others. For a het-
erogeneous sample, a candidate gene with an M-value 
below 1 can be considered as a reliable reference gene 
[11]. The CV for a gene was obtained by calculating the ra-
tio of the standard deviation (a) to the mean (µ) of relative 
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quantities (CV = <J / µ). For a heterogeneous panel, a value 
below 50% is proposed as satisfactory [11]. 
To rank the genes that satisfied the above criteria, 
M-values were recalculated after stepwise elimination 
of the worst candidate. To assess the number of refer-
ence genes needed for an accurate normalization, the 
effect of inclusion of a supplementary gene to those 
already considered stable was determined by calculat-
ing the pairwise variation of the added candidate 
gene to the others (standard deviation of logarithmic-
ally transformed expression ratios). If this pairwise 
variation goes below 0.15, no supplementary gene is 
needed [9]. 
Results 
Reference genes used in the SNI model 
We found 484 articles in the PubMed database using 
"spared nerve injury" as keywords. Twenty-six arti-
cles were retrieved with semi-quantitative PCR or 
RT-qPCR performed in the rat DRG, spinal cord or 
brain. Despite its rigorous validation never having 
been mentioned, GAPDH was the most commonly 
used reference gene (16 times) whether in the DRG 
or in the dorsal horn. This was followed by Actb 
and 185 (3 times), HPRTl (twice) and HMBS (once). 
HPRTl and 185 were the only two reference genes 
with validation in the rat SNI mode! (Table 2). 
Validation of reference genes in spinal cord dorsal horn 
over time after SNI 
Rat spinal cord dorsal horn samples were analyzed 
in an overall panel without differentiating any 
timepoints, i.e. throughout a temporal follow-up with 
naive animais, 2nd, 4·th, 7th, lOth, 14th and 21st 
postoperative day animais. The pairwise comparison 
of al! the potential reference genes (Actb, 185, 
GAPDH, RPL13a, RPL29, HPRTl and HMBS) calcu-
lated using geNorm resulted in M-values below 0.5 
for ail but the 185 gene, which showed 0.52 (Figure 1). Ail 
genes were below the M-value eut-off of 1.0 pro-
posed for a heterogeneous panel. CV ranged from 
20% for HMBS to 34% for GAPDH and RPL13a, i.e. 
below the 50% eut-off for stability in a heterogeneous 
panel. 
Validation of reference genes in DRG after SNI in a 
time-dependent panel 
As for the dorsal horn, DRG samples were analyzed in 
an overall panel without differentiating any timepoints. 
M-values were below 1.0 and CV below 50% for Actb, 
GAPDH, RPL13a, RPL29, HPRTl and HMBS. The 185 
reference gene had the worst M-value, at 0.8, but this 
was still acceptable within the selection. However, we 
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Table 2 List of reference genes in the rat spared nerve injury model 
Article PCR method Sample 
Kanda et al., 2013 [25] PCR L4/L5 SC 
Zhou et al., 2013 [26] RT-qPCR L4/LS DRG 
Kashimoto et al., 2013 [27] RT-qPCR L4/L5 SC 
Shankarappa et al., 2012 [28] RT2 Profiler PCR array L4/LS DRG 
lnquimbert et al., 2012 [29] PCR L4/L5 DH 
Zapata et al., 2012 [30] RT-qPCR RVM 
Samadet al., 2013 [31] PCR L4 DRG 
Kobayashi et al., 2012 [32] RT-qPCR L4/L5 SC 
Liu et al., 2012 [33] RT-qPCR L4-L6 SC 
Tochiki et al., 2012 [34] PCR L4-L6 DH 
Okubo et al., 2012 [35] RT-qPCR L4-L5 SC 
Del Rey et al., 2011 [36] PCR hippocampus 
Kühlein et al., 2011 [37] RT-qPCR and PCR DH and DRG 
Yamanaka et al., 2011 [38] RT-qPCR L4, 5 DRG 
de Novellis et al., 2011 [39] RT-qPCR mPFC 
Vega-Avelaira et al., 2009 [40] PCR L4/L5 DRG 
Costigan et al., 2009 [41 J PCR L4/L5 DH 
Okubo et al., 2010 [42] RT-qPCR L4-L5 SC 
Staaf et al., 2009 [43] Taqman Low Density Arrays L4 DRG 
Moss et al., 2008 [44] PCR L4/5 DRG 
Berta et al., 2008 [45] PCR L4 and L5 DRGs 
Millecamps et al., 2007 [46] PCR mPFC 
Moss et al., 2007 [47) PCR L 4/LS dorsal horn 
Apkarian et al., 2006 [48) RT-qPCR brainstem, thalamus, and prefrontal cortex 
Pertin et al., 2005 [49) PCR L4/L5 DRG 
Takahashi et al., 2003 [50] RT-qPCR L5 DRG 
Llterature search ln the PubMed database of studies using semi-quantitative PCR or RT-qPCR in the rat SNI model. 
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Reference genes Validation 
GAPDH no 
GAPDH no 
GAPDH no 
HPRT1 validated 1 
GAPDH no 
18S and HMBS 110 
GAPDH no 
GAPDH no 
Actb no 
HPRTl no 
GAPDH 110 
not mentioned no 
Actb and 18S no 
GAPDH no 
Actb no 
GAPDH no 
GAPDH no 
GAPDH no 
18S validated2 
GAPDH no 
GAPDH no 
GAPDH no 
GAPDH no 
GAPDH no 
GAPDH no 
GAPDH no 
PCR semi-quantitative polymerase chain reaction, RT-qPCR reverse transcription quantitative real-time polymerase chain reaction, SC spinal cord, DRG dorsal root 
ganglion, OH dorsal horn, RVM rostral ventromedial medulla, PL-IL prelimbic and infralimbic, mPFC media! prefrontal cortex. 
1 HPRTl validated among 5 reference genes. 
2 See Discussion. 
rejected it from our gene sample because of its 61% CV 
(Figure 1). 
Ranking of reference genes 
\X! e reanalyzed the 7 tested reference genes (Actb, 
GAPDH, RPL13a, RPL29, HPRTl, HMB5 and 185) to 
rank them. After each step, the gene with the highest 
M-value was eliminated until we obtained the tv.10 
most stable genes from the list. No further discrimin-
ation was possible. 
ln the spinal cord dorsal horn, the 2 most stable genes 
remaining after the stepwise elimination were RPL29 
and RPL13a, and then in increasing order GAPDH, 
Actb, HMB5, HPRTl and 185 (Figure 2A). 
ln the DRG, the 2 most stable genes remaining after 
the stepwise elimination were HPRTl and Actb, and 
then in increasing order RPL29, RPL13a, HMB5, 
GAPDH and 185 (Figure 2B). The latter is used because 
this ranking only takes into account the M-value and 
not the CV. 
Minimal number of reference genes 
In the dorsal horn samples, the calculation of pair-
wise variations resulted in values much lower than 
0.15 along the entire time course and in all samples. 
Using the two best reference genes the pairwise vari-
ation in dorsal horn was 0.07 (Figure 3). The addition 
of a supplementary reference gene did not signifi-
cantly lower the pairwise variation. Results for DRG 
were similar, with a low pairwise variation of 0.05 if 
only the two most stable reference genes were taken 
in consideration. 
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A Dorsal horn 
M-value CV 
1 .............................................. -.................................................. 100~6 
0.5 50% -------------------------------------------· 
0 0% +-"~-r-'-~-r-'-~-.---'~-r-"~~~___.~ 
ACTB RPL29 RPL13a HMBS GAPDH HPRT 185 ACTB RPL29 RPL13a HMBS GAPDH HPRT 185 
B Dorsal root ganglion 
M-value CV 
1 -------------------------------------------· 100% 
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Figure 1 Analysis of reference gene stability. Assessrnent of reference gene stability, in the ipsilateral dorsal horn (A) and L4-L5 dorsal root 
ganglia (B) in the rat spared nerve injury rnodel using M-value (left) frorn the gel\Jorm algorithm and coefficient of variation {CV) (right). 
Candidate genes are classified from left to right by increasing order of M-value, fro1.-1 most to least stable. The eut-off for stability is 1 for M-value 
and 50% for CV (dotted line). 
\Ve performed the same analysis using the least stable 
reference genes on our list for dorsal horn and DRG, 
and their pairwise variation was still below 0.15. 
Discussion 
Here, we tested the stability of seven candidate refer-
ence genes according to the geNorm algorithm to 
ensure accurate RT-qPCR normalization. M-values 
below 1.0 together with CV lower than 50% for 
Actb, GAPDH, RPL13a, RPL29, HPRTl, and HMBS 
identified these candidate genes as good controls in 
the rat SNI mode! in the spinal cord dorsal horn 
and DRG. The lSS gene could not be validated in 
DRG because of a CV above 50%. 
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Figure 2 Ranking of reference genes. Stepwise calculation of stability by excluding the least stable gene and averaging the remaining 
M-values in the spinal cord dorsal horn (A) and the dorsal root ganglia (B). lnsert: list of reference genes ranked from the most to least stable. 
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Figure 3 Determination of the optimal number of control genes for accu rate normalization. Determination of the number of reference 
genes to consider for an accurate normalization in spinal cord dorsal horn {A} and dorsal root ganglia {B} by calculating pairwise variation (V} 
after stepwise elimination of the worst reference gene. 
After SNI, gene expression changes in both sites can 
be enormous compared to the baseline and also over 
time [51]. Because of this heterogeneity, meticulous RT-
qPCR procedures relying on MIQE recommendations 
are essential to obtain consistent data. The most frequently 
chosen reference gene for RT-qPCR normalization after 
SNI in the rat is GAPDH, but its expression level had, to 
our knowledge, never been confirmed as being stable in 
this mode! (Table 2). Here, we confirm that GAPDH is 
a good candidate gene, even if it is not the most stable 
in our series. 
The only 2 reference genes with previously mentioned 
validation in the rat SNI mode! are HPRTl and 18S. 
HPRTl was used by Shankarappa et al. in DRG [28] at 2 
timepoints after injury and chosen from among 5 differ-
ent reference genes on an array. After showing that 18S 
had a very low variation of Cq values in ail data sets, 
from both SNI and naive groups, Staaf et al. used it to 
normalize and compare the expression of the transient 
receptor potential (TRP) family of genes in DRG after 
SNI. They mentioned neither ranking bet\veen the differ-
ent reference genes, nor the criteria used to choose 18S 
from among their list of them [43]. These demonstra-
tions are part of the workflow of RT-qPCR arrays where 
several reference genes are proposed, and their analysis 
is usually fully integrated in the procedure. 
GeNorm is a popular algorithm for assessing different 
reference genes from a given panel [9,11]. The calcula-
tion of M-values permits measurement of an average 
variation in the expression ratios of one potential ref-
erence gene with the others and consequently in-
forms us whether the tested gene is constantly expressed 
compared to them. The CV of relative quantities of a gene 
merely reflects the dispersion of its expression level. It has 
been previously demonstrated that a CV below 25% was 
typically observed in stable reference genes as long as the 
experimental conditions were homogeneous. In a hetero-
geneous panel, such as in the present study, a CV below 
50% is acceptable [11]. As it measures the gene-specific 
variation, the CV in assessing the stability of a reference 
gene assumes a standardization of the procedures for all 
samples. Taken togethei~ M-values and the CV are very 
useful tools for determining the most accurate reference 
genes because the information that they convey is different. 
Ail our candidate genes satisfied an M-value eut-off below 
1.0 for a heterogeneous panel. 18S, despite its acceptable 
M-value, failed to satisfy the CV eut-off in DRG. Consider-
ing these results 18S could not be validated as a stable ref-
erence gene. 
The more the M-value tends to zero, the more the 
candidate gene is stable compared to the other tested 
genes. Hence the stability of tlle different genes can be 
ranked. A first approximate classification was established 
after analvzing ail the samples together (Figure 1). Actb, 
RPL13a and RPL29 were the 3 best genes in both tis-
sues. A potentially more accurate classification can 
be performed if M-values are recalculated in a series of 
steps, after elimination of the worst scoring gene at each 
step. At the end, the t\vo most reliable reference genes re-
main, but they cannot be further discriminated by defin-
ition of the M-value (Figure 2). Interestingly the ranking 
differed between dorsal horn and DRG. We again found 
RPL 29 and RPL13a to be the most stable genes in the 
spinal cord dorsal horn, however, in the DRG, HPRTl and 
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Actb were the best, followed immediately by RPL13a and 
RPL29. In the present study, differences in· the ranking 
were very slight, and the former "rough" method would 
have been sufficient. In other circumstances, or ·with an-
other panel of candidate genes, it could be useful to com-
pare them further until a definitive ranking is obtained, so 
as to choose only the best contrai genes from amongst the 
candidates. M-value calculations and subsequent ranking 
were also performed independently for each different tüne 
point (data not shown) without being able to identify any 
time-dependent regulation. The primat)' goal of this study 
was to validate some suitable RT-qPCR reference genes at 
different time points, in different tissues, in a widely used 
neuropathie pain mode!. 
According to MIQE guidelines, the use of a single 
reference gene is not enough to compensate for the 
intrinsic variation within that reference gene and 
normalization against several reference genes should 
be performed [7,9]. To define the minimal number of 
necessary reference genes, the pairwise variation per-
mits an assessment of whether the removal of the 
worst reference gene may result in a greater variation 
(Figure 3). Here, in both DRG and dorsal horn, the 
two best candidate genes were sufficient to ensure an 
accurate normalization. This demonstration allows us 
to state that in our mode!, using only the two best 
reference genes would be sufficient: namely RPL 29 
and RPL13a in the spinal cord dorsal horn and 
HPRTl and Actb in the DRG. However, even the 
worst pair satisfied stability criteria, with a pairwise 
variation less than 0.15. In fact, all pairs of validated 
reference genes (not 185 because of its CV above 
50%) provided a robust validation in both tissues and at all 
time points. GAPDH is often used, but according to MIQE 
guidelines it should not be used alone. 
The criterion for choosing a reference gene is more 
than just its stability. 185, for example, is disputed as a 
reference gene by some authors who argue that it by far 
exceeds the mRNA quantity of most genes of interest 
and it might be absent from pure mRNA extracts [9]. 
Conclusions 
\X!e validated 7 reference genes in the spinal cord dorsal 
horn: (Actin beta (Actb), Glyceraldehyde-3-phosphate de-
hydrogenase (GAPDH), ribosomal proteins L13a (RPL13a) 
and L29 (RPL29), hypoxanthine phosphoribosyltransferase 
1 (HPRTl), hydroxymethylbilane synthase (HMBS) and 
185. In DRG, 185 did not fulfill all our criteria and could 
not be retained as a good reference gene, although the 
other 6 were. \X!e were able to show that in both tissues, 
using any tvvo of the proposed stable reference genes is suf-
ficient to ensure an accurate validation. \Ve were also able 
to confirm the stability of GAPDH, which is the most 
commonly used reference gene in the SNI mode!, 
Page 8 of 9 
but it should be used in combination with another 
control gene. 
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